A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention

Memorias do Instituto Oswaldo Cruz

Volumn 108, Issue 7, 2013, Pages 873-880

  Machado de Assis, Girley Francisco ^a   Diniz, Glaucia Alessio ^a   Montoya, Roberto Araújo ^b   Dias, João Carlos Pinto ^c   Coura, José Rodrigues ^c   Machado Coelho, George Luiz Lins ^a   Albajar Viñas, Pedro ^d   Torres, Rosália Morais ^e   de Lana, Marta ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b Organização Pan Americana da Saúde   (Colombia)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d Organização Mundial da Saúde   (Switzerland)

^e FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Benznidazole; Chagas disease; Etiological treatment; Serological and clinical evaluation; Trypanosoma cruzi

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; NITROIMIDAZOLE DERIVATIVE;

ADOLESCENT; ADULT; CASE CONTROL STUDY; CHAGAS DISEASE; CHILD; DISEASE COURSE; FEMALE; HUMAN; IMMUNOLOGY; MALE; PARASITOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; TRYPANOSOMA CRUZI; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHAGAS DISEASE; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NITROIMIDAZOLES; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDIES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; YOUNG ADULT;

EID: 84886923918     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-0276130122     Document Type: Article

References (50)

1. Amato Neto V 1998. Terapêutica da forma crônica da doença de Chagas. Tratamento específico da infecção pelo Trypanosoma cruzi. Arq Bras Cardiol 70: 63-64.
2. Andrade ALSS, Zicker F, Oliveira RM, Silva SA, Luquetti AO, Travassos LR, Almeida IC, Andrade SS, Andrade JG, Martelli CMT 1996. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
3. Ávila HA, Sigman DS, Cohen LM, Millikan S, Simpson L 1991. Polymerase chain reaction amplification of Trypanosoma cruzi kinetoplast minicircle DNA isolated from whole blood lysates: diagnosis of chronic Chagas disease. Mol Biochem Parasitol 48: 211-221.
4. Braga MS, Lauria-Pires L, Argañaraz ER, Nascimento RJ, Teixeira ARL 2000. Persistent infection in chronic Chagas disease patient treated with anti-Trypanosoma cruzi nitroderivates. Rev Inst Med Trop Sao Paulo 42: 157-161.
5. Britto C, Cardoso MAB, Wincker P, Morel CM 1993. A simple protocol for the physical cleavage of Trypanosoma cruzi kinetoplast DNA present in blood samples and its use in polymerase chain reaction (PCR)-based diagnosis of chronic Chagas disease. Mem Inst Oswaldo Cruz 88: 171-172.
6. Britto CC 2009. Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations. Mem Inst Oswaldo Cruz 104 (Suppl. I): 122-135.
7. Cançado JR 2002. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 29-37.
8. Castro AM, Luquetti AO, Rassi A, Chiari E, Galvão LMC 2006. Detection of parasitemia profiles by blood culture after treatment of human chronic Trypanosoma cruzi infection. Parasitol Res 99: 379-383.
9. Chagas C 1909. Nova tripanozomiaze humana. Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz 1: 159-218.
10. Chiari E, Dias JCP, Lana M, Chiari CA 1989. Hemocultures for the parasitological diagnosis of human chronic Chagas disease. Rev Soc Bras Med Trop 22: 19-23.
11. Coura JR, Abreu LL, Wilcox HPF, Petana W 1997. Estudo comparativo controlado com emprego de benzonidazole, nifurtimox e placebo na forma crônica da doença de Chagas em uma área de campo com transmissão interrompida. I Avaliação preliminar. Rev Soc Bras Med Trop 30: 139-144.
12. Coura JR, Borges-Pereira J 2011. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz 106: 641-645.
13. Coura JR, de Castro SL 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.
14. de Lana M, Lopes LA, Martins HR, Bahia MT, Machado-de-Assis GF, Wendling AP, Martins-Filho OA, Montoya RA, Dias JCP, Albajar-Viñas P, Coura JR 2009. Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. Mem Inst Oswaldo Cruz 104: 1139-1147.
15. Dias JCP 1999. Epidemiologia. In Z Brener, ZA Andrade, M Barral-Netto (org.), Trypanosoma cruzi e doença de Chagas, Guanabara Koogan, Rio de Janeiro, p. 48-74.
16. Fabbro DL, Streiger ML, Arias ED, Bizai ML, Del Barco M, Amicone NA 2007. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 40: 1-10.
17. Fabbro DS, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, Amicone N 2000. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42: 99-109.
18. Fernandes CD, Tiecher FM, Balbinot MM, Liarte DB, Scholl D, Steindel M, Romanha A 2009. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz 104: 27-32.
19. Fragata-Filho AA, da Silva MA, Boainain E 1995. Etiologic treatment of acute and chronic Chagas disease. Sao Paulo Med J 113: 867-872.
20. Gallerano RH, Sosa RR 2001. Resultados de un estudio a largo plazo con drogas antiparasitarias en infectados chagásicos crônicos. Rev Fed Arg Cardiol 30: 289-296.
21. Gallerano RH, Sosa RR 2000. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Cordoba 57: 135-162.
22. Galvão LMC, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade ALSS 2003. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol 41: 5066-5070.
23. Gomes ML, Galvão LM, Macedo AM, Pena SD, Chiari E 1999. Chagas disease diagnosis: comparative analysis of parasitologic, molecular and serologic methods. Am J Trop Med Hyg 60: 205-210.
24. Gomes ML, Macedo AM, Vago AR, Pena SDJ, Galvão LMC, Chiari E 1998. Trypanosoma cruzi: optimization of polymerase chain reaction for detection in human blood. Exp Parasitol 88: 28-33.
25. Guedes PMM, Fietto JLR, Lana M, Bahia MT 2006. Advances in Chagas disease chemotherapy. Antiinfect Agents Med Chem 5: 175-186.
26. Ianni BM, Arteaga E, Mady CL 1993. Uso do benzonidazol em chagásicos na forma indeterminada: resultados a longo prazo. Arq Bras Cardiol 61 (Suppl. 2): 130.
27. Ianni BM, Mady C 1998. Terapêutica da forma crônica da doença de Chagas. É eficaz o tratamento etiológico? Arq Bras Cardiol 70: 59-61.
28. Junqueira ACV, Chiari E, Wincker P 1996. Comparison of the polymerase chain reaction with two classical parasitological methods for the diagnosis of Chagas disease in an endemic region of northeastern Brazil. Trans R Soc Trop Med Hyg 90: 129-132.
29. Lauria-Pires L, Braga M, Vexenat AC, Nitz N, Simões-Barbosa A, Tinoco DL, Teixeira ARL 2000. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am J Trop Med Hyg 63: 111-118.
30. Macêdo VO, Silveira CA 1987. Perspectiva da terapêutica específica na doença de Chagas. Experiência na forma indeterminada. Rev Soc Bras Med Trop 20 (Suppl. 2): 24-26.
31. Marin-Neto JA, Rassi Jr A, Avezum Jr A, Mattos AC, Rassi A 2009. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104 (Suppl. I): 319-324.
32. Miranda L, Campos G, Marins N, Lobo V 1994. História natural da forma crônica da doença de Chagas x tratamento específico. Rev Centro-Oeste Cardiol 1: 25-29.
33. Montoya RA 1998. Morbidade da doença de Chagas no município de Berilo, Minas Gerais, Brasil. Estudos seccional e longitudinal da cardiopatia chagásica crônica (1987 - 1997), PhD Thesis, Instituto Oswaldo Cruz, Rio de Janeiro, 153 pp.
34. MS Ministério da Saúde 2005. Consenso brasileiro em doença de Chagas. Rev Soc Bras Med Trop 38 (Suppl. 3): 1-29.
35. OMS/OPAS - Organización Mundial de la Salud/Organización Panamericana de la Salud 1974. Aspectos clínicos de la enfermedad de Chagas. Informe de una reunión conjunta OMS/OPAS de investigadores. Bol Oficina Sanit Panam 76: 141-158.
36. Prata A 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100.
37. Santos FR, Pena SD, Epplen JT 1993. Genetic and population study of a Y-linked tetranucleotide repeat DNA polymorphism with a simple non-isotopic technique. Hum Genet 90: 655-656.
38. Santos LS, Torres RM, Machado-de-Assis GF, Bahia MT, Martins HR, Teixeira-Carvalho A, Coelho-dos-Reis JGA, Albajar-Viñas P, Martins-Filho OA, Lana M 2012. In house ELISA method to analyze anti-Trypanosoma cruzi IgG reactivity for differential and evaluation of Chagas disease morbidity. Rev Soc Bras Med Trop 45: 35-44.
39. Schmunis GA 2007. Epidemiology of Chagas disease in non endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 102 (Suppl. I): 75-85.
40. Segura MA, de Raspi EM, Basombrio MA 1994. Reversibility of muscle and heart lesions in chronic Trypanosoma cruzi infected mice after late trypanomicidal treatment. Mem Inst Oswaldo Cruz 89: 213-216.
41. Sosa-Estani S 1993. Tratamiento específico anti-T. cruzi. In R Madoeri, C Madoeri, MI Cámera (eds.), Actualización en enfermedad de Chagas, Organización Congreso Facultad de Medicina, Buenos Aires, p. 279-287.
42. Sosa-Estani S, Segura EL 2006. Etiological treatment in patients infected by Trypanosoma cruzi: experiences in Argentina. Current Opin Infect Dis 19: 583-587.
43. Sosa-Estani S, Segura EL, Ruiz AMR, Velazquez E, Porcel BM, Yampotis C 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg 59: 526-529.
44. Suasnabar DF, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, Amicone N 2000. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42: 99-109.
45. Viotti R, Vigliano C, Álvarez MG, Lococo B, Petti M, Bertocchi G, Armenti A, de Rissio AM, Cooley G, Tarleton R, Laucella S 2011. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis 5: e1314.
46. Viotti R, Vigliano C, Armenti H, Segura E 1994. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-162.
47. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A 2006. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734.
48. Voller A, Draper C, Bidwell DE 1975. Microplate enzyme-linked immunosorbent assay (ELISA) for Chagas disease. Lancet 305: 426-428.
49. WHO - World Health Organization 2002. Control of Chagas disease. Second report of the WHO Expert Committee. WHO Technical Report Series 905, WHO, Geneva, 120 pp.
50. WHO - World Health Organization 2010. First WHO report on neglected tropical diseases. Working to overcome the global impact of neglected tropical diseases. Available from: who.int/neglected_diseases/2010report/en/.